Calcineurin Inhibitor Sparing After Kidney Transplantation
Status:
Completed
Trial end date:
2014-04-03
Target enrollment:
Participant gender:
Summary
Reducing drug side effects is a key issue in transplantation. One class of drugs commonly
used, calcineurin inhibitors (CNIs), is associated with negative side effects, namely,
toxicity to the transplanted kidney. In some patients, this toxicity is thought to be
associated with loss of transplant function in those who have had their transplants for many
years. The introduction of new immunosuppression medications however, has provided the
opportunity to minimize or avoid CNIs, which may reduce the occurrence of toxicity to the
kidney.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute
Collaborators:
Genzyme, a Sanofi Company Roche Pharma AG Wyeth is now a wholly owned subsidiary of Pfizer